New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
07:35 EDTENDPEndo Health reports 2013 non-cash charges of $495M
Endo Health Solutions has completed its annual goodwill and in-process research and development impairment analysis for 2013 and plans to record in fiscal 2013, a pre-tax, non-cash asset impairment charge of approximately $495M primarily related to goodwill attributable to the company's acquisition of American Medical Systems. During Q4 2013, the company also recorded a pre-tax, non-cash charge of approximately $31M to increase the company's product liability reserve to approximately $520M for all known, pending and estimated future claims primarily related to vaginal mesh cases. The non-cash charges will not affect the company's 2013 adjusted financial results; however, 2013 GAAP earnings per share are now expected to be materially below previously announced guidance of 95c-$1.10.
News For ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:11 EDTENDPEndo price target raised to $90 from $77 at Sterne Agee
Subscribe for More Information
December 16, 2014
08:58 EDTENDPEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
December 11, 2014
17:04 EDTENDPEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
December 9, 2014
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
December 8, 2014
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use